Last reviewed · How we verify
NCT03090178: ACTISLEEP
Sleep & Quality of Life Evaluation of Patients With Atopic Dermatitis Based on E-diary on a Smartphone Application and Actigraphy
NA trial testing electronic-Patient Report Outcome and wear of a wristband actigraph in Atopic Dermatitis Eczema in 52 participants. Completed in 15 June 2018.
15 June 2018
Quick facts
| Lead sponsor | Ad scientiam |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | other |
| Enrollment | 52 |
| Start date | 2 June 2017 |
| Primary completion | 15 June 2018 |
| Estimated completion | 15 June 2018 |
| Sites | 1 location across France |
Drugs / interventions tested
- electronic-Patient Report Outcome and wear of a wristband actigraph
Conditions studied
- Atopic Dermatitis Eczema — all drugs for Atopic Dermatitis Eczema →
Sponsor
Ad scientiam
Who can join
Adults 18 to 120, any sex, with Atopic Dermatitis Eczema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Atopic dermatitis is a chronic disease with a high impact on patient's quality of life. Nocturnal pruritus is one of the main symptoms affecting quality of life. Treatment efficacy is generally measured by healthcare professionals during consultations with both questioning and visual examination of the lesions. Quality of Life (QoL) can also be evaluated retrospectively with the Dermatology Life Quality Index (DLQI) scale. Collecting data retrospectively introduces a significant recall bias that can be addressed by collecting data in Real World (RW). Real World data collection is prospective and take place within the patient's own environment. While data collection is generally done with diaries, it has been demonstrated that smartphone and connected devices were able to produce more precise and granular data than traditional methods.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03090178
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Atopic Dermatitis Eczema
Currently open trials in the same condition.
- NCT06855745 — Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD. · Phase 2 · recruiting
- NCT06850311 — Herbal Ointment in Treating Atopic Dermatitis Topically · Phase 2, PHASE3 · recruiting
- NCT06024499 — Phase 2 Trial of HY209gel in Atopic Dermatitis Patients · Phase 2 · active not recruiting
- NCT06004986 — DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema · Phase 4 · recruiting
- NCT05316805 — China Type II Inflammatory Skin Disease Clinical Research and Standardized Diagnosis and Treatment Project · recruiting
Other Ad scientiam trials
Trials by the same sponsor.
- NCT06386133 — Chronic Fatigue in Multiple Sclerosis: MS Copilot Boost Solution Compared to Standard Care · NA · not yet recruiting
- NCT06922942 — MSCopilot Users' Feedback in Real Life - Outcomes Regarding Integration in Patients' pathWay and Users' ExpeRience · NA · active not recruiting
- NCT06147778 — Performances and Safety of MuCopilot, a Digital Tool for the Unsupervised Objective Assessment of Cystic Fibrosis · NA · completed
- NCT05564936 — The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis · NA · recruiting
- NCT05816122 — MS-DETECT: Early Detection of Multiple Sclerosis Progression With MSCopilot® Detect · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03090178 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ad scientiam
- Last refreshed: 8 August 2018
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03090178.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing